Bank of Montreal’s Janux Therapeutics JANX Stock Holding History

Bank of Montreal’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-98,429	Closed	-$1.08M	–	4154
2023 Q3	$1.08M	Buy	+98,429	New	+$1.14M	﹤0.01%	2015

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal's JANX Position: Q4 2023 in Review

Bank of Montreal sold out of Janux Therapeutics (JANX) in Q4 2023, closing a stake of 98,429 shares — an estimated $1.08M sold.

Bank of Montreal first reported a position in JANX in Q3 2023 and held it in 1 quarter. The position peaked at $1.08M in Q3 2023. 64 funds tracked by Wall St. Rank hold JANX as of Q4 2023.

Bank of Montreal reported no remaining Janux Therapeutics position as of Q4 2023 after selling out during the quarter.
Bank of Montreal sold 98,429 Janux Therapeutics shares in Q4 2023, an estimated $1.08M.
Bank of Montreal first reported a position in Janux Therapeutics in Q3 2023 and held it in 1 quarter.
Bank of Montreal's Janux Therapeutics position peaked at $1.08M in Q3 2023.
64 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2023.

Based on Bank of Montreal's 13F filing for Q4 2023, filed 8 Feb 2024.